Compare AstraZeneca plc (AZN) vs Nu Holdings Ltd (NU) Price & Performance

AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.

The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.

NU Holdings trades at $13.67, down 0.65% on the day, with strong fundamental performance including 26.72% net income margin and 30.04% ROE. The company shows impressive revenue growth from $3.0B in 2022 to $10.63B in 2025, with technical indicators showing a bullish trend supported by moving averages. Recent approval for banking operations in Mexico with 15 million customers provides significant growth catalyst.

NU presents a compelling growth story with expanding profitability and Latin American market penetration. The stock trades below analyst consensus target of $14.98, offering potential upside, though currency headwinds and credit risks in emerging markets remain concerns. With 54.55% analyst buy ratings and strong cash flow generation, the long-term outlook appears positive despite recent earnings misses.